Alvogen has been picking up HDA awards for several years in a row now and on this occasion the two prestigious prizes were for HDA top company of the year and National product launch of the year for Alvogen’s very successful launch of Oseltamivir, the first generic equivalent to Tamiflu® (oseltamivir phosphate), which has delivered significant savings for patients and health providers last season.
Since 1959, the DIANA awards have been honoring HDA-member manufacturers that develop innovative new product introductions and promotions for the healthcare distribution industry. Recipients also are recognized for fostering exceptional trading partner relationships with HDA distribution members, advancing trade relations and creating business practices that benefit the entire healthcare supply chain.
"The 2017 DIANA winners set the standard for excellence through their hard work, creativity and collaborative spirit," said HDA President and CEO John M. Gray. "Their dedication to advancing the pharmaceutical supply chain, and the patients it serves, helps fuel this industry and our organization. All of us at HDA congratulate them on their achievements."
William Hill, Michael Olivi, and David Gann were in Phoenix to pick up the awards on Alvogen’s behalf. They said they were delighted to be receiving this recognition in such a challenging market place and congratulated the entire USGX and Norwich teams for their hard work.